Open Access Research

Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort

Jason H Karnes12, Taimour Y Langaee2, Caitrin W McDonough2, Shin-Wen Chang2, Miguel Ramos2, James R Catlin Jr2, Octavio E Casanova2, Yan Gong2, Carl J Pepine3, Julie A Johnson23 and Rhonda M Cooper-DeHoff23*

Author Affiliations

1 Division of Clinical Pharmacology, Vanderbilt University, 1275 Medical Research Building IV, Nashville, TN, 37232-0575, USA

2 Department of Pharmacotherapy and Translational Research, University of Florida, HSC PO Box 100486, Gainesville, FL, 32610-0486, USA

3 Division of Cardiovascular Medicine, University of Florida, PO Box 100277, Gainesville, FL, 32610-0486, USA

For all author emails, please log on.

Journal of Translational Medicine 2013, 11:12  doi:10.1186/1479-5876-11-12

Published: 9 January 2013

Abstract

Background

Recently, the high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American populations. We sought to investigate the HMGA1-diabetes association and to characterize IVS5-13insC allele frequencies and linkage disequilibrium (LD) in 3,070 Caucasian, Hispanic, and African American patients from the INternational VErapamil SR-Trandolapril STudy (INVEST).

Methods

INVEST was a randomized, multicenter trial comparing two antihypertensive treatment strategies in an ethnically diverse cohort of hypertensive, coronary artery disease patients. Controls, who were diabetes-free throughout the study, and type 2 diabetes cases, either prevalent or incident, were genotyped for IVS5-13insC using Taqman®, confirmed with Pyrosequencing and Sanger sequencing. For LD analysis, genotyping for eight additional HMGA1 single nucleotide polymorphisms (SNPs) was performed using the Illumina® HumanCVD BeadChip. We used logistic regression to test association of the HMGA1 IVS5-13insC and diabetes, adjusted for age, gender, body mass index, and percentage European, African, and Native American ancestry.

Results

We observed IVS5-13insC minor allele frequencies consistent with previous literature in Caucasians and African Americans (0.03 in cases and 0.04 in controls for both race/ethnic groups), and higher frequencies in Hispanics (0.07 in cases and 0.07 in controls). The IVS5-13insC was not associated with type 2 diabetes overall (odds ratio 0.98 [0.76-1.26], p=0.88) or in any race/ethnic group. Pairwise LD (r2) of IVS5-13insC and rs9394200, a SNP previously used as a tag SNP for IVS5-13insC, was low (r2=0.47 in Caucasians, r2=0.25 in Hispanics, and r2=0.06 in African Americans). Furthermore, in silico analysis suggested a lack of functional consequences for the IVS5-13insC variant.

Conclusions

Our results suggest that IVS5-13insC is not a functional variant and not associated with type 2 diabetes in an ethnically diverse, hypertensive, coronary artery disease population. Larger, more adequately powered studies need to be performed to confirm our findings.

Trial registration

clinicaltrials.gov (NCT00133692)

Keywords:
HMGA1; Type 2 diabetes; Genetics